All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2020-01-13T11:00:58.000Z

Lacutamab phase II trial in advanced T-cell lymphomas placed on partial hold by the FDA

Jan 13, 2020
Share:

Bookmark this article

The U.S. Food & Drug Administration (FDA) has placed a partial clinical hold on the TELLOMAK (NCT03902184) trial which is evaluating the safety and efficacy of lacutamab (IPH4102) in patients with advanced T-cell lymphomas, (TCLs).1  This decision comes after discussions with regulatory authorities about Good Manufacturing Practice (GMP) deficiencies at a subcontractor site which managed the fill and finish operations of the lacutamab vials.

TELLOMAK trial is a phase II, open-label, multi-cohort, multi-center study investigating the safety and clinical activity of lacutamab alone or in combination with chemotherapy. Enrollment of new patients has been suspended until a new GCP-certified batch of lacutamab is available, however, patients currently enrolled on the trial may continue treatment if they re-consent.

Lacutamab is a first-in-class anti-killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2) monoclonal antibody. KIR3DL2 is an inhibitory receptor which is expressed abundantly across cutaneous TCL (CTCL) tumor cells but not normal immune cells. Binding of lacutamab to KIR3DL2 on tumor cells initiates the recruitment of natural killer cells and subsequent immune-mediated depletion of tumor cells.1

Lacutamab has shown promising clinical activity and an acceptable safety profile in a phase I study (NCT02593045) of patients with relapsed/refractory CTCL.2 In August 2014, lacutamab was granted orphan drug status in the European Union and United States for the treatment of CTCL.3 In January 2019, the FDA granted Fast Track designation for lacutamab for the treatment of adults with relapsed or refractory Sézary syndrome (an aggressive form of CTCL).3

For more information on TCL, see the Lymphoma Hub article here.

  1. Innate Pharma. Innate Pharma Provides Update from Regulatory Agencies on Lacutamab Tellomak Trial. January 9 2020. https://www.innate-pharma.com/en/news-events/press-releases/innate-pharma-provides-update-regulatory-agencies-lacutamab-tellomak-trial. Published; January 9 2020, [Accessed: January 10 2020]
  2. Bagot, M. et al., IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019 Aug; 20(8):1160–1170. DOI: 10.1016/S1470-2045(19)30320-1
  3. Innate Pharma. LACUTAMAB / IPH4102: FIRST-IN-CLASS ANTI-KIR3DL2 MAB.https://www.innate-pharma.com/en/pipeline/lacutamab/iph4102-first-class-anti-kir3dl2-mab. [Accessed: January 10 2020]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
46 votes - 78 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox